TVGN-489

February 7, 2025 WARREN, N.J., Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, met the Center for the Biomedical Advanced Research and Development Authority (BARDA) TechWatch team. The discussion focused on Tevogen Bio’s affordable and scalable ExacTcell technology, the positive results of its proof-of-concept (POC) clinical trial for TVGN 489, the use of Artificial Intelligence in its process and future manufacturing capabilities. During the meeting, Tevogen Bio discussed ExacTcell’s unique ability to rapidly adapt to emerging viral threats, positioning it as a potential countermeasure to safeguard public health. Tevogen Bio will follow up with key federal entities and continue to update stakeholders. VITAL Biotech Accelerator Program Department of Defense – Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Antivirals and Antitoxins Branch within BARDA’s Division of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation. Tevogen Communications T: 1 877 TEVOGEN, Ext 701 communications@Tevogen.com

January 27, 2025 Warren, N.J., Dr. Ryan Saadi, Chairman and founding CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, congratulates Lynne Patton on being appointed Deputy Assistant to the President and Director of Minority Outreach. Ms. Patton will join the Office of Public Liaison and will be responsible for ensuring that President Trump continues to build upon his Election Day support from Blacks, Latinos and Women. Ms. Patton has been one of the Trump family’s longest serving and most trusted aides. Previously, Ms. Patton was the Regional Administrator for Federal Region II at the U.S. Department of Housing and Urban Development (HUD) and Senior Advisor to Secretary Ben Carson. At HUD, Ms. Patton worked tirelessly to bring accountability, reform and results to some of the most challenging housing issues facing our country. From championing the rights of underserved communities to exposing corruption and mismanagement within public housing systems, Lynne consistently fought for fairness and opportunity, earning her the bipartisan respect of industry peers and local elected officials alike. Lynne’s deep connection to the issues affecting minority communities combined with her remarkable interpersonal skills, makes her the ideal person to lead this critical outreach effort. “Being appointed Deputy Assistant to the President and Director of Minority Outreach is both an honor and an opportunity to continue my bipartisan efforts on behalf of the White House in supporting important issues impacting all Americans with a focus on underserved communities, both rural and urban,” commented Ms. Patton. Dr. Saadi added, “Business success can be an unattainable concept unless it contributes to societal prosperity. As a pioneering AI biotech, we are committed to supporting the President’s initiative to advance affordable medical innovation.” Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation. This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases, cancer and neurological disorders, including TVGN 489 for the treatment of COVID-19 and Long COVID; Tevogen’s ability to develop additional product candidates, including through use of Tevogen’s ExacTcell platform; the anticipated benefits of ExacTcell; expectations regarding Tevogen’s future clinical trials; and Tevogen’s ability to generate revenue in the future. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the “Business Combination”) on Tevogen’s business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law. Tevogen Communications T: 1 877 TEVOGEN, Ext 701 communications@Tevogen.com